[{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"d99ff91a-cf24-4676-a6eb-63f5be5bef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05928780","created_at":"2023-07-03T16:10:36.813Z","updated_at":"2024-07-02T16:35:44.110Z","phase":"Phase 1/2","brief_title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)","source_id_and_acronym":"NCT05928780","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib) • AiRuiEn (rezvilutamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-07-03"},{"id":"827d408e-ae28-47c5-90db-df752d156207","acronym":"FUTURE","url":"https://clinicaltrials.gov/study/NCT03805399","created_at":"2021-01-18T18:48:30.838Z","updated_at":"2024-07-02T16:36:05.726Z","phase":"Phase 1/2","brief_title":"FUSCC Refractory TNBC Umbrella (FUTURE)","source_id_and_acronym":"NCT03805399 - FUTURE","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/18/2018","start_date":" 10/18/2018","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-08-10"},{"id":"6fe8f0e9-8178-43af-8474-eda668b88de5","acronym":"MULAN","url":"https://clinicaltrials.gov/study/NCT04355858","created_at":"2021-01-18T21:03:24.371Z","updated_at":"2024-07-02T16:36:06.637Z","phase":"Phase 2","brief_title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","source_id_and_acronym":"NCT04355858 - MULAN","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR7390 • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 319","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-07-26"}]